Drug Patent Bills Run Out of Time in Congress
Drug Patent Bills Run Out of Time in Congress
Drug Patent Bills Run Out of Time in Congress
Key points
اہم نکات
मुख्य बातें
- Bills to curb drug patents are running out of time as Congress changes hands, and pending measures expire when this Congress ends on January 3.
- The measures would limit drugmakers' use of patents to delay cheaper generic drugs, but with a new Congress taking over in January, supporters face a short lame-duck window to pass them.
- Bills to curb drug patents are running out of time as Congress changes hands, and pending measures expire when this Congress ends on January 3.
- The measures would limit drugmakers' use of patents to delay cheaper generic drugs, but with a new Congress taking over in January, supporters face a short lame-duck window to pass them.
- Bills to curb drug patents are running out of time as Congress changes hands, and pending measures expire when this Congress ends on January 3.
- The measures would limit drugmakers' use of patents to delay cheaper generic drugs, but with a new Congress taking over in January, supporters face a short lame-duck window to pass them.
Bills to curb drug patents are running out of time as Congress changes hands, and pending measures expire when this Congress ends on January 3. The measures would limit drugmakers' use of patents to delay cheaper generic drugs, but with a new Congress taking over in January, supporters face a short lame-duck window to pass them.
Bills to curb drug patents are running out of time as Congress changes hands, and pending measures expire when this Congress ends on January 3. The measures would limit drugmakers' use of patents to delay cheaper generic drugs, but with a new Congress taking over in January, supporters face a short lame-duck window to pass them.
Bills to curb drug patents are running out of time as Congress changes hands, and pending measures expire when this Congress ends on January 3. The measures would limit drugmakers' use of patents to delay cheaper generic drugs, but with a new Congress taking over in January, supporters face a short lame-duck window to pass them.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।